Pall T. Onundarson: The Fiix Test Team Was Awarded UNIVANTS 2025!
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, proudly reposted from Eduardo Freggiaro on LinkedIn:
”The Fiix test team was awarded UNIVANTS 2025 Team of Distinction and got to meet the UNIVANTS of HealthCare Excellence executives at the ADLM (previously AACC) 2025 in Chicago.
The prize is awarded by 7 important healthcare associations around the world.
These people see the potential of improved patient care through replacing the conventional monitoring method of warfarin and VKAs (PT-INR) with a new test that more accurately reflects the antithrombotic effect, reduces anticoagulation variability and enhances effectiveness of anticoagulation with the old drug class that everybody had written off and thought they knew all about…
But now clinical pharmacology needs some revision.
Fortunately, it is very easy to replace the PT-INR with the Fiix-NR: same instruments, same staff, mostly the same dosing protocols.
The Fiix test is CE marked in Europe, still for scientific use elsewhere, manufactured by Hart Biologicals Limited in England.”
Eduardo Freggiaro, President of FBA, Executive Board member of IFCC, shared an honoring post on LinkedIn:
”During the ADLM congress in Chicago I had the opportunity and honor to participate in this photo with the winners of the highest recognition of the UNIVANTS 2025 award.
Also present were previous winners, Abbott executives and the CEO of the ADLM.
Congratulations to Professor Pall T. Onundarson, M.D. and his team for the excellent work they have done.”
Stay updated on the emerging with Hemostasis Today.
-
Oct 11, 2025, 09:06Natalia Peres Martinez - Surgical Bleed: Replacing Gut Feeling With Guided Thinking
-
Oct 11, 2025, 09:00Muhammad Ali - Hematology In Pakistan: The Silent Revolution In Diagnosis And A Blueprint For Growth
-
Oct 11, 2025, 08:50Robert Zeiser: New Insights and Timeless Lessons in Transplantation
-
Oct 11, 2025, 08:39Mildred Lundgren: These 5 Proposals Are A Clear Road Map for The Future And We Support Them Wholeheartedly
-
Oct 11, 2025, 08:33RPTH Journal: Does Fasting Affect Anticoagulant Therapy? - The Effects Of Fasting During Ramadan
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 11, 2025, 18:47Endovascular Today: SYMPHONY-PE Trial and Advances in Pulmonary Embolism Treatment
-
Oct 11, 2025, 08:49Rodrigo Assar: We Are Pushing the Boundaries by Using Computational Approaches
-
Oct 11, 2025, 08:48Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
-
Oct 11, 2025, 08:34Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 11, 2025, 08:57Jeff June - Seeing The Invisible: How Spatial Biology Is Opening A New Chapter In Stroke Care
-
Oct 11, 2025, 08:11Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
-
Oct 11, 2025, 08:07Britta Diebel: This Has Been An Intense, Good Week, Although IPAW Actually Lasts All Year Long
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?